Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
CDXS Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Codexis, Inc.NASDAQ: CDXS
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue rises 97.7% from a year ago
Deferred revenue stood at $866K at the end of Q1 FY2026, up 97.7% from a year earlier and down 87.6% from the prior quarter. Over 3 fiscal years it compounded at -20.1% a year.
Context
- Deferred revenue amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Deferred revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether deferred revenue keeps rising in the next quarterly balance sheet after a +97.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 7.01M USD
- Year-over-year change
- +1902.6%
- 4-year CAGR
- +28.3%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.01M | +1902.6% |
| FY2024 | 2024-12-31 | 350K | -96.5% |
| FY2023 | 2023-12-31 | 10.12M | -26.3% |
| FY2022 | 2022-12-31 | 13.73M | +430.9% |
| FY2021 | 2021-12-31 | 2.59M | — |
Deferred Revenue vs competitors
How CDXS compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +97.7% is the 2nd highest of 5, against a peer median of +8.6%.
- Deferred revenue amounts to 0.7% of total assets for CDXS, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $10.12M USD | -53.1% | -9.1% | 3.1% | |
| Mar 2026 | $6.83M USD | — | — | 13.2% | |
| Mar 2026 | $2.94M USD | +70.4% | -27.2% | 1.0% | |
| Dec 2025 | €2.82M EUR | +358.4% | -24.5% | 4.5% | |
| Mar 2026 | $866K USD | +97.7% | -20.1% | 0.7% | |
| Mar 2026 | $402K USD | -94.7% | -74.1% | 0.7% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding CDXS) | — | +8.6% | -25.9% | 0.7% | |
Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 116.8M | 113.98M | 65.12M | 19.26M | 50.79M |
| Short-term Investments | 0 | 0 | 0 | 54.19M | 27.42M |
| Net Receivables | 37.65M | 40.87M | 19.93M | 18.88M | 10.73M |
| Inventory | 1.16M | 2.03M | 2.69M | 1.8M | 1.82M |
| Other Current Assets | 579K | 521K | 5.74M | 4.63M | 6.06M |
| Total Current Assets | 161.89M | 162.89M | 93.47M | 98.77M | 96.82M |
| Property, Plant & Equipment (Net) | 65.46M | 61.88M | 28.62M | 42.9M | 43.53M |
| Goodwill | 3.24M | 3.24M | 2.46M | 2.46M | 2.46M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 14M | 20.51M | 9.7M | 2.8M | 2.5M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.8M | 1.87M | 2.31M | 2.08M | 2.5M |
| Total Non-current Assets | 84.5M | 87.5M | 43.1M | 50.24M | 50.98M |
| Total Assets | 246.38M | 250.39M | 136.56M | 149.01M | 147.8M |
| Account Payables | 3M | 3.25M | 5.95M | 2.84M | 1.55M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.59M | 13.73M | 10.12M | 350K | 7.01M |
| Other Current Liabilities | 11.12M | 11.45M | 11.25M | 11.41M | 11.04M |
| Total Current Liabilities | 33.37M | 49.07M | 35.83M | 23.65M | 25.32M |
| Long-term Debt | 0 | 0 | 0 | 28.91M | 40.11M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 3.75M | 16.88M | 640K | 100K | 360K |
| Other Non-current Liabilities | 1.31M | 1.37M | 1.23M | 1.27M | 1.33M |
| Total Non-current Liabilities | 48.62M | 56.53M | 14.12M | 58.44M | 71.95M |
| Total Liabilities | 81.99M | 105.6M | 49.95M | 82.08M | 97.27M |
| Common Stock | 6K | 6K | 7K | 8K | 9K |
| Retained Earnings | (387.7M) | (421.29M) | (497.53M) | (562.81M) | (606.78M) |
| Accumulated OCI | 0 | 0 | 0 | 52K | 8K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 164.39M | 144.8M | 86.62M | 66.93M | 50.53M |
| Total Debt | 47.65M | 43.64M | 16.02M | 59.9M | 73.21M |
| Net Debt | (69.14M) | (70.35M) | (49.09M) | 40.63M | 22.42M |
Codexis, Inc.
NASDAQ:CDXS
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.